A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
ERROR: Incorrect data type for operator or @Function: Text expected, Uproleselan
The goal of this clinical research study is to learn if adding uproleselan to standard chemotherapy can help to control acute myeloid leukemia (AML). The safety of this study drug will also be studied. Researchers also want to learn about additional effects of adding the study drug to standard chemotherapy, to learn if the study drug may affect how often patients get mouth sores/blisters, and to learn how long the study drug stays in patients’ bloodstreams. In this study, uproleselan will be compared to a placebo. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: ERROR: Incorrect data type for operator or @Function: Text expected, Uproleselan
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: GlycoMimetics, Inc.
IRB Review and Approval Date: 10/05/2018
Recruitment Status: Open
Projected Accrual: 380
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: